{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61","upperLimit":"84","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Progression Free Survival at 3 years. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.\n\npegfilgrastim\n\ncisplatin\n\nifosfamide\n\npaclitaxel","id":"OG000","title":"Paclitaxel, Ifosfamide, and Cisplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Percentage of Participants With Progression Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}